This study explored the therapeutic effect of trimebutine maleate dispersible tablets combined with berberine on PI-IBS rats with liver depression and spleen deficiency.Fifty male rats were divided into five groups:no...This study explored the therapeutic effect of trimebutine maleate dispersible tablets combined with berberine on PI-IBS rats with liver depression and spleen deficiency.Fifty male rats were divided into five groups:normal,model,berberine(XB),trimebutine(QM),and combination(XB+QM).The PI-IBS model was established using maternal separation,TNBS perfusion,and chronic restraint.After 20 days of drug intervention,DAI,CMDI,TDI,AWR scores,histopathology,and expression levels of c-Fos,VIP,NOS,and CHAT in the hippocampus and colon were assessed.The model group showed significant gut and brain changes,while the combination group(XB+QM)improved fecal characteristics,reduced inflammation,regulated brain-gut peptide expression,and alleviated visceral hypersensitivity and colon tissue damage(P<0.05).展开更多
Objective: To explore the effect of trimebutine in combined with alprazolam on the gastrointestinal hormones and living quality in patients with diarrhea-type IBS (IBS-D). Methods: A total of 117 patients with IBS-D w...Objective: To explore the effect of trimebutine in combined with alprazolam on the gastrointestinal hormones and living quality in patients with diarrhea-type IBS (IBS-D). Methods: A total of 117 patients with IBS-D who were admitted in our hospital were included in the study and randomized into the control group (n=58) and the treatment group (n=59). The patients in the control group were given trimebutine;while the patients in the treatment group were given trimebutine in combined with alprazolam. The patients in the two groups were continuously treated for 4 weeks. The levels of gastrointestinal hormones and brain-gut peptide before and after treatment in the two groups were detected and compared. SF-36 was used to analyze the living quality before and after treatment in the two groups. Results: MOT;GAS;SP;and 5-HT levels after treatment in the two groups were significantly reduced;while VIP;SS;CCK;and CGRP levels and SF-36 score in each dimension were significantly elevated;and the comparison between the two groups was statistically significant. Conclusions:Trimebutine in combined with alprazolam in the treatment of IBS-D can significantly improve the gastrointestinal hormones and brain-gut peptide;and enhance the living quality;with a significant efficacy.展开更多
Objective:To evaluate the clinical efficacy ofFuzi Lizhong Wan and trimebutine in the treatment of diarrhea irritab1e bowel syndrome.Methods:A tota1 of 90 patients with diarrhea irritable Dow1 syndrome were divided in...Objective:To evaluate the clinical efficacy ofFuzi Lizhong Wan and trimebutine in the treatment of diarrhea irritab1e bowel syndrome.Methods:A tota1 of 90 patients with diarrhea irritable Dow1 syndrome were divided intocontro1 group(n=45)and treatment group(n=45)using the random.number table method.Patients in the control group were po administered withtrimebutine 0.2 g.three time daily for 4 weeks.Patients in the treatment group were po administered with Fuzi Lizhong Wan 9 g,three time daily for 4 weeks on the basis of the control group.The clinical efficacy and the TCM symptom scores were evaluated after treatment.The serological indicators in two groups were compared before and after treatment.Results:After treatment,the clinica1 efficacy and the TCM symptom scores in treatment group were significantly 1ower than that in contro1 group(P<0.05).The 1evels of serological indicators in both groups improved significant1y,and those in the treatment group were better than the control group(P<0.05).Conclusion:Combined therapy of Fuzi Lizhong Wan and trimebutine in the treatment of diarrhea type irritable bowe1 syndrome has a significant effect,which canrelieve clinical symptom;and reduce visceral sensitivity,and improve leve1s of inflammatory and quality of life.So it is suggested to be applied.展开更多
基金Science and Technology Fund Project of Guizhou Provincial Health Commission(Project No.:gawkj2021-225).
文摘This study explored the therapeutic effect of trimebutine maleate dispersible tablets combined with berberine on PI-IBS rats with liver depression and spleen deficiency.Fifty male rats were divided into five groups:normal,model,berberine(XB),trimebutine(QM),and combination(XB+QM).The PI-IBS model was established using maternal separation,TNBS perfusion,and chronic restraint.After 20 days of drug intervention,DAI,CMDI,TDI,AWR scores,histopathology,and expression levels of c-Fos,VIP,NOS,and CHAT in the hippocampus and colon were assessed.The model group showed significant gut and brain changes,while the combination group(XB+QM)improved fecal characteristics,reduced inflammation,regulated brain-gut peptide expression,and alleviated visceral hypersensitivity and colon tissue damage(P<0.05).
文摘Objective: To explore the effect of trimebutine in combined with alprazolam on the gastrointestinal hormones and living quality in patients with diarrhea-type IBS (IBS-D). Methods: A total of 117 patients with IBS-D who were admitted in our hospital were included in the study and randomized into the control group (n=58) and the treatment group (n=59). The patients in the control group were given trimebutine;while the patients in the treatment group were given trimebutine in combined with alprazolam. The patients in the two groups were continuously treated for 4 weeks. The levels of gastrointestinal hormones and brain-gut peptide before and after treatment in the two groups were detected and compared. SF-36 was used to analyze the living quality before and after treatment in the two groups. Results: MOT;GAS;SP;and 5-HT levels after treatment in the two groups were significantly reduced;while VIP;SS;CCK;and CGRP levels and SF-36 score in each dimension were significantly elevated;and the comparison between the two groups was statistically significant. Conclusions:Trimebutine in combined with alprazolam in the treatment of IBS-D can significantly improve the gastrointestinal hormones and brain-gut peptide;and enhance the living quality;with a significant efficacy.
基金Youth Scientific Research Fund project of Affiliated Hospital of Hebei University(2016Q003)。
文摘Objective:To evaluate the clinical efficacy ofFuzi Lizhong Wan and trimebutine in the treatment of diarrhea irritab1e bowel syndrome.Methods:A tota1 of 90 patients with diarrhea irritable Dow1 syndrome were divided intocontro1 group(n=45)and treatment group(n=45)using the random.number table method.Patients in the control group were po administered withtrimebutine 0.2 g.three time daily for 4 weeks.Patients in the treatment group were po administered with Fuzi Lizhong Wan 9 g,three time daily for 4 weeks on the basis of the control group.The clinical efficacy and the TCM symptom scores were evaluated after treatment.The serological indicators in two groups were compared before and after treatment.Results:After treatment,the clinica1 efficacy and the TCM symptom scores in treatment group were significantly 1ower than that in contro1 group(P<0.05).The 1evels of serological indicators in both groups improved significant1y,and those in the treatment group were better than the control group(P<0.05).Conclusion:Combined therapy of Fuzi Lizhong Wan and trimebutine in the treatment of diarrhea type irritable bowe1 syndrome has a significant effect,which canrelieve clinical symptom;and reduce visceral sensitivity,and improve leve1s of inflammatory and quality of life.So it is suggested to be applied.
